利拉鲁肽对肥胖2型糖尿病患者成纤维细胞生长因子21和蛋白酪氨酸磷酸酶1B的影响

Effects of liraglutide on fibroblast growth factor 21 and protein tyrosine phosphatase 1B in patients with obesity type 2 diabetes mellitus

目的探讨利拉鲁肽改善肥胖2型糖尿病(type 2 diabetes mellitus,T2DM)患者血清成纤维细胞生长因子21(fibroblast growth factor 21,FGF21)与蛋白酪氨酸磷酸酶1B(protein tyrosine phosphatase 1B,PTP1B)的效果。方法选取2019年3月至2020年1月于河北省保定市第一中心医院内分泌科住院部接受治疗的肥胖T2DM患者80例,根据随机数字表法分为对照组及观察组,每组40例。对照组采用口服药物治疗,观察组在对照组基础上加用利拉鲁肽,两组疗程均为3个月,对比两组治疗前后体质量指数(body mass index,BMI)、腰围、臀围、空腹血糖(fasting blood glucose,FBG)、餐后2 h血糖(2-hour postprandial blood glucose,2hPG)、糖化血红蛋白(glycosylated hemoglobin A1c,HbA1c)、血清FGF21及PTP1B浓度,分析血清FGF21和PTP1B相关性。结果治疗前,两组BMI、腰围、臀围、FBG、2hPG、HbA1c、FGF21、PTP1B水平差异均无统计学意义(P>0.05);治疗后,两组上述指标水平均降低,且观察组低于对照组,差异有统计学意义(P<0.05)。血清FGF21和PTP1B呈正相关(r=0.45,P<0.05)。结论利拉鲁肽可明显降低肥胖T2DM患者脂肪含量,改善血糖水平,降低血清FGF21、PTP1B水平,疗效较佳。

Objective To explore the effects of liraglutide on the levels of serum fibroblast growth factor 21(FGF21)and protein tyrosine phosphatase 1B(PTP1B)in patients with obesity type 2 diabetes mellitus(T2DM).Methods A total of 80 obesity T2DM patients who were treated in the inpatient department of endocrinology department of first central hospital of Baoding city,Hebei province from March 2019 to January 2020 were randomly divided into control group and observation group,with 40 cases in each group.The control group was treated with oral drugs,and the observation group was treated with liraglutide on the basis of the control group.The course of treatment of both groups was 3 months.The body mass index(BMI),waist circumference,hip circumference,fasting blood glucose(FBG),2-hour postprandial blood glucose(2hPG),glycosylated hemoglobin A1c(HbA1c),serum FGF21 and PTP1B concentrations were compared between the two groups before and after treatment.The correlation between serum FGF21 and PTP1B were analyzed.Results Before treatment,there was no significant difference in BMI,waist circumference,hip circumference,FBG,2hPBG,HbA1c,FGF21 and PTP1B between the two groups(P>0.05).After treatment,the levels of the above indexes in the two groups decreased,and the levels in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).There was a positive correlation between serum FGF21 and PTP1B(r=0.45,P<0.05).Conclusion Liraglutide can significantly reduce the fat content,improve the blood glucose level,decrease the levels of serum FGF21 and PTP1B in patients with obesity T2DM,and improve therapeutic effect.